Telithromycin, a new ketolide, exhibits potent activity against respiratory pathogens, including resistant strains.
Methods
Five days of telithromycin (800 mg once daily) was compared with 10 days of cefuroxime axetil (250 mg twice daily) in subjects (n = 593) with acute bacterial maxillary sinusitis (ABMS). Bacteriologic sampling was accomplished by sinus puncture or nasal endoscopy. The primary efficacy variable was clinical outcome at the posttherapy/test-of-cure evaluation in clinically evaluable patients.
Results
Clinical cure was achieved in 85.2% of telithromycin patients and 82.0% of cefuroxime axetil patients (difference in proportions, 3.2%; 95% confidence interval, 27.1–13.4%). Satisfactory bacteriologic response rates were comparable. Treatment-emergent adverse events for both drugs were mild or moderate. The most frequently reported treatment-emergent adverse events were nausea and diarrhea.
Conclusion
Once-daily telithromycin for 5 days was equivalent in efficacy to twice-daily cefuroxime axetil for 10 days in patients with ABMS. Telithromycin is a suitable option for short-course therapy of ABMS.
Get full access to this article
View all access options for this article.
References
1.
PooleM.D.A focus on acute sinusitis in adults: changes in disease management.Am J Med106: 38S–47S, 1999.
2.
Sinus, and Allergy Health Partnership.Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.Otolaryngol Head Neck Surg123: S4–S31, 2000.
3.
Jousimies-SomerH., SavolainenS., and YlikoskiJ.Bacteriological findings of acute maxillary sinusitis in young adults.J Clin Microbiol26: 1919–1925, 1988.
ZeckelM.L., JohnsD.Jr., MasicaD.N.Twice-daily dosing of loracarbef 200 mg versus 400 mg in the treatment of patients with acute maxillary sinusitis.Clin Ther17: 214–230, 1995.
GoochW.M.IIIAntimicrobial management of acute and chronic sinusitis.Manag Care Interface12: 92–94, 1999.
8.
FelminghamD., GrünebergR.N. and the Alexander Project Group. The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections.J Antimicrob Chemother45: 191–203, 2000.
9.
HadleyJ.A.The microbiology and management of acute and chronic rhinosinusitis.Curr Infect Dis Rep3: 209–216, 2001.
10.
BarryA.L., FuchsP.C., BrownS.D.Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).Antimicrob Agents Chemother42: 945–946, 1998.
11.
BarryA.L., FuchsP.C., and BrownS.D.In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae.Antimicrob Agents Chemother42: 2138–2140, 1998.
12.
BiedenbachD.J., BarrettM.S., and JonesR.N.Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains.Diagn Microbiol Infect Dis31: 349–353, 1998.
13.
JalavaJ., KatajaJ., SeppäläH.In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species.Antimicrob Agents Chemother45: 789–793, 2001.
14.
NamourF., WesselsD.H., PascualM.H.Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses.Antimicrob Agents Chemother45: 170–175, 2001.
15.
LenfantB., SultanE., WableC.Pharmacokinetics of 800 mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers. [Abstract A49]. ASM Press; Herndon, VA. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24–27, 1998.
16.
MiyamotoN., MurakamiS., YajinK.Pharmacokinetic study of a new ketolide antimicrobial telithromycin (HMR 3647) in otorhinolaryngology.ASM Press; Herndon, VA. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 17–20, 2000.
17.
CalhounK.H., and HokansonJ.A.Multicenter comparison of clarithromycin and amoxycillin in the treatment of acute maxillary sinusitis.Arch Fam Med2: 837–840, 1993.
18.
CamachoA.E., CoboR., OtteJ.Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis.Am J Med93: 271–276, 1992.
19.
MatthewsB.L., KohutR.I., EdelsteinD.R.Evaluation of cefixime in the treatment of bacterial maxillary sinusitis.South Med J86: 329–333, 1993.
20.
SiegertR., GehannoP., NikolaidisP.A comparison of the safety and efficacy of moxifloxacin (BAY 12–8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group.Respir Med94: 337–344, 2000.
21.
WilliamsJ.W.Jr., HollemanD.R.Jr., SamsaG.P.Randomized controlled trial of 3 vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis.JAMA273: 1015–1021, 1995.
22.
CasianoR.R.Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis.Am J Med91(suppl. 3A): 27S–30S, 1991.
23.
KhongT.K.Shortened therapies in acute sinusitis.Hosp Pract31(suppl. 1): 11–13, 1996.
24.
GehannoP., BeauvillainC., BobinS.Short therapy with amoxicillin-clavulanate and corticosteroids in acute sinusitis: results of a multicentre study in adults.Scand J Infect Dis32: 679–684, 2000.
25.
PichiceroM.Short courses of antibiotic in acute otitis media and sinusitis infections.J Int Med Res28(suppl. 1): 25A–36A, 2000.
26.
BaqueroF., BarrettJ.F., CourvalinP.Epidemiology and mechanisms of resistance among respiratory tract pathogens.Clin Microbiol Infect4(suppl. 2): S19–S26, 1998.
27.
JacobsM.R., BajaksouzianS., ZillesA.Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study.Antimicrob Agents Che-mother43: 1901–1908, 1999.
28.
HobanD.J., ZhanelG.G., and KarlowskyJ.A.In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.Diagn Microbiol Infect Dis35: 37–44, 1999.
